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Abstract 
Purposes: The aim of this study was to determine the effects of nutritional status at the start of highly active anti-
retroviral therapy on treatment outcomes among HIV/AIDS patients taking HAART at Jimma University Specialized 
Hospital.
Methods: We performed a retrospective cohort study involving 340 adults who started highly active anti-retroviral 
therapy. The patients have been clinically followed for 2 years. Data were extracted from paper based medical charts 
by trained data collectors from January 30 to February 28, 2014 using data collection format. We entered data into Epi 
data version 3.1 and then exported to SPSS for windows version 21. Predictors of CD4 change were identified using 
multivariable linear regression model. Time to an event (death) was estimated by Kaplan–Meier and predictors of 
mortality were identified by Cox proportional hazard model.
Results: Out of 340 patients, 42 patients died during the follow-up. Twenty-five (59.5 %) deaths were from malnour-
ished group. Age, baseline CD4, sex, baseline HAART and marital status were significant predictors of immunologic 
recovery at different time points. Malnutrition was associated with lower CD4 recovery and greater hazard of death.
Conclusions: Malnutrition tends to decrease CD4 recovery and predisposes patient to early death.
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Background
Treatment of HIV-infected patients with highly active 
antiretroviral therapy (ART) leads to immune reconsti-
tution as shown by increases in CD4 lymphocyte counts, 
decreased risk of opportunistic infections and improved 
survival [1, 2]. However, all patients do not have an opti-
mal response to therapy. Some patients have slow and 
incomplete recovery of immune function and remain at 
greater risk of developing opportunistic infections and 
death than those who show more rapid immune recon-
stitution [3]. Patients may die with an undetectable viral 
load and adequate CD4 count recovery [2]. Therefore, 
adjunctive treatments that accelerate the recovery of 
immune function or that address other related causes 
of mortality may provide additional gains in survival in 
patients with HIV starting HAART.
Even though, previous studies showed malnutrition 
was independent predictor of death in patients taking 
HAART [4–8] in different countries, there were conflict-
ing results on impact of malnutrition at HAART initia-
tion on immunologic recovery at different time periods 
after HAART initiation, some studies showed malnutri-
tion does not prevent an excellent response to HAART 
[9] while, other suggest poor immunological response 
[10].
However, no previous study had holistically examined 
the impact on survival, CD4 recovery and occurrence of 
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opportunistic infections of malnutrition at the time of 
starting HAART. Furthermore, there were few studies in 
Africa and no study done in Ethiopia that examined effect 
of malnutrition at the initiation of HAART on treatment 
outcome. It is possible that malnutrition may impair the 
immune response to HAART, prolong the period during 
which patients are at risk of opportunistic infection and 
directly or indirectly increasing the risk of death. Malnu-
trition may therefore, represent a potentially reversible 




We conducted retrospective cohort study at Jimma 
University Specialized Hospital, the only teaching and 
referral hospital with bed capacity of 450 in the South 
Western part of the country providing specialized 
health service for approximately 9000 inpatients and 
80,000 outpatients each. The ART clinic of the hospi-
tal started providing service to people living with HIV/
AIDS (PLWA) in 2002. Since establishment the clinic 
had 3700 patients following care and treatment [11]. 
The primary data was collected from September 11, 
2006 to September 10, 2011. Data was extracted from 
the medical record from January 30 to February 28, 
2014. The sample size was calculated by single propor-
tion formula used for cohort studies, which assumes 
proportion of mortality in malnourished group to be 
61.8  % and proportion of mortality in well-nourished 
group to be 46.8 with 95  % confidence interval, 80  % 
power and 1:1 ratio of unexposed versus exposed. 
The sample size calculated was 340 patients; one hun-
dred seventy (170) patients in both malnourished and 
well-nourished groups. The medical records of adult 
patients who started HAART between September 2006 
and September 2011 were isolated. The isolated medi-
cal charts were categorized into malnourished and 
well-nourished groups based on their BMI at the start 
of HAART. Malnutrition was defined as a BMI  <18.5, 
while BMI  ≥18.5 was defined as a well-nourished as 
per WHO criteria. All patients whose age was greater 
than 14 were included in the study. Pregnant women’s 
(BMI and nutrient metabolism vary during pregnancy), 
patients with incomplete data on weight, height and 
outcome variables, transferred-out during follow-up 
were excluded from the study. The data were collected 
by clinically trained data collectors using data collection 
tool adapted from national ART clinic intake form, ART 
follow up form and anti-retroviral drugs and patient 
information sheet. The endpoint of this study was death. 
The patients were followed until the occurrence of event 
(death) or until 2  years (end of study). Patients who 
were alive at the end of study were censored. The sur-
vival time was calculated in days using date of starting 
treatment and date of an event or date censored.
Statistical methods
The data was cleaned, edited and completed using Epi 
data version 3.1 and exported to SPSS for window version 
21 for analysis. The main analysis in this study was lin-
ear regression for CD4 recovery and survival analysis for 
death. Variables with p value of <0.25 in bivariate analy-
sis and BMI were fitted to multivariable cox-proportional 
analysis model to identify independent predictors of CD4 
change at all time points. Kaplan–Meier survival analysis 
was done to estimate the survival time. Log-rank test was 
used to compare the KM curves for two or more catego-
ries of patients on HAART. Predictors of event (death) 
over a period of time t, was analyzed by Cox propor-
tional hazard model. The level of significance was set at 
p value less than 0.05 and 95 % confidence intervals (CI) 
were used throughout. Multi-collinerity was checked for 





We followed all patients for 2  years. There were a total 
of 42 deaths during the follow-up period. Twenty-five 
(59.5  %) deaths were from malnourished group. The 
mean age of the study participants was 34 [IQR 26–38] 
years. The median age was 30  years and 200 (58.8  %) 
patients were females. Mean baseline BMI was 1.50 [IQR 
1.0–2.00] kg/m2. The median baseline CD4 count was 
144.5 [IQR 89–209] cells/mm3 (Tables 1, 2).
Immunologic recovery
Immunologic recovery at  6  months Age was the only 
independent predictor of immunologic recovery. For 
1 year increase in the age of the patient, CD4 decreases by 
3.40 cells/mm3 (p = 0.003). CD4 count of malnourished 
group decreases by 12.40 cells/mm3 (p = 0.500) compared 
to well-nourished group (Table 3).
Immunologic recovery at  12  months Age and baseline 
CD4 count were independent predictors of immunologic 
recovery. For 1 year increase in the age of the patient CD4 
decreases by 1.91 cells/mm3 (p =  0.005). CD4 count of 
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patients with baseline CD4 count in the range of 100–199 
increases by 201.29 cells/mm3 (p =  0.047) compared to 
patients with baseline CD4 count greater than 350. CD4 
count of malnourished patients decreases by 21.5 cells/
mm3 (p = 0.321) compared with well-nourished group at 
12 months (Table 4).
Immunologic recovery at 24 months In multivariate lin-
ear regression analysis age, sex, marital status and base-
line HAART were significant predictors of immunologic 
recovery at 24th month. For 1  year increase in age of 
the patients, CD4 increases by 2 cells/mm3 (p = 0.005). 
Females had increased CD4 count by 104.3 cells/mm3 
compared to males. Married patients had 138.56 cells/
mm3 (p  =  0.005) higher CD4 count compared to wid-
owed patients. CD4 count of patients who started treat-
ment with Stavudine based regimen increases by 87.49 
cells/mm3 (p = 0.036) compared to CD4 count of patients 
Table 1 Baseline demographic characteristics and  asso-
ciated mortality and  opportunistic infections of  340 HIV-
infected patients in Jimma University Specialized Hospital, 








 Male 140 (41.2) 19 (45.2) 38 (45.8)
 Female 200 (58.8) 23 (54.8) 45 (54.2)
BMI
 <18.5 170 (50) 25 (59.5) 55 (66.3)
 ≥18.5 170 (50) 17 (40.5) 28 (33.7)
Religion
 Orthodox 203 (59.7) 29 (69) 44 (53)
 Muslim 100 (29.4) 13 (31) 26 (31.3)
 Protestant 31 (9.1) 0 11 (13.3)
 Catholic 2 (0.6) 0 1 (1.2)
 Others 2 (0.6) 0 0
Age (years)
 <30 174 (51.2) 21 (50.0) 46 (55.4)
 30–39 94 (27.6) 11 (26.2) 21 (25.3)
 40–49 57 (16.8) 6 (14.3) 12 (14.5)
 >50 15 (4.4) 4 (9.5) 4 (4.8)
Marital status
 Single 43 (12.6) 7 (16.7) 10 (12.0)
 Married 116 (34.1) 16 (38.1) 36 (43.4)
 Widowed 22 (6.5) 1 (2.4) 5 (6.0)




98 (28.8) 14 (33.3) 19 (22.9)
 Merchant 5 (1.5) 0 (0) 2 (2.4)
 Unemployed 189 (55.6) 25 (59.5) 51 (61.4)
 Private org 37 (10.9) 2 (4.8) 10 (12.0)
 NGO’s 5 (1.5) 1 (2.4) 0 (0)
Educational status
 Not educated 69 (20.3) 4 (9.5) 24 (28.9)
 Primary 122 (35.9) 17 (40.5) 25 (30.1)
 Secondary 106 (31.2) 14 (33.3) 21 (25.3)
 Tertiary 42 (12.4) 7 (1.7) 12 (14.4)
Table 2 Baseline clinical characteristics and  associated 
mortality and  opportunistic infections of  HIV-infected 
patients in  Jimma University Specialized Hospital, 








 Stage I 65 (19.1) 6 (14.3) 15 (18.1)
 Stage II 95 (27.9) 9 (21.4) 15 (18.1)
 Stage III 144 (42.4) 17 (40.5) 44 (53.0)




219 (64.4) 19 (45.2) 60 (72.3)
 Zidovudine 
based
72 (21.2) 12 (28.6) 18 (21.7)
 Tenofovir 
based
49 (14.4) 11 (26.2) 5 (6.0)
Base line CD4
 >350 5 (1.5) 0 (0.0) 2 (2.4)
 200–350 94 (27.6) 7 (16.7) 19 (22.9)
 100–199 139 (40.9) 15 (35.7) 37 (44.6)
 <100 102 (30.0) 20 (47.6) 25 (30.1)
Risky behaviour
 Yes 120 (35.3) 14 (33.3) 58 (69.9)
 No 220 (64.7) 28 (67.7) 25 (30.1)
Cotrimoxazole prophylaxis
 Yes 330 (97.1) 42 (100.0) 81 (97.6)
 No 10 (2.9) 0 (0.0) 2 (2.4)
Fluconazole prophylaxis
 Yes 20 (5.9) 8 (19.1) 5 (6.0)
 No 320 (94.1) 34 (80.9) 78 (94.0)
INH prophylaxis
 Yes 62 (18.2) 7 (16.7) 20 (24.1)
 No 278 (81.8) 35 (83.3) 63 (75.9)
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who started with Tenofovir based regimen. Malnourished 
group has 22.4 cells/mm3 lower increases in CD4 count 
compared to well-nourished group (Table 5).
Death In Kaplan–Meier bivariate cox-proportional 
analysis survival times significantly differ among groups of 
baseline CD4 (p = 0.014), WHO clinical stage (p = 0.022), 
baseline HAART (p  =  0.010) and Fluconazole prophy-
laxis (p = 0.000). Even though, malnourished patients had 
shorter survival times compared to well-nourished group, 
it was not statistically significant (p = 0.170) (Fig. 1).
In multivariable cox proportional model four variables 
were found to be significant predictors of mortality. These 
were Zidovudine based regimen (AHR  =  4.182, 95  % 
CI 1.550, 11.282, p  =  0.005), Tenofovir (AHR  =  5.156, 
p  =  0.001), Fluconazole prophylaxis (HR  =  5.639, 
95  % CI 1.811, 17.563, p  =  0.003), age above 50  years 
(AHR  =  4.783, p  =  0.040) and CD4 greater than 200 
(HR = 0.287, 95 % CI 0.097, 0.848, p = 0.002). Malnour-
ished patients were 1.3 times at risk of death compared 
to well-nourished group [AHR = 1.460, 95 % CI (0.648, 
3.287), p = 0.361] (Table 6).
Discussion
There was no significant difference between malnour-
ished and well-nourished patients in terms of CD4 recov-
ery after HAART initiation. This finding is similar with 
reports by Elizabeth et al. who reported nutritional status 
at the start of HAART as measured by BMI, FFMI, FMI 
and skin folds did not predict good post HAART CD4 
change at 6, 12 and 24 months in a cohort of HIV infected 
Rwanda women [12]. There was no significant difference 
in CD4 recovery between malnourished patients and 
well-nourished patients after initiation of HAART [12]. 
Likewise, Brandon et al. showed that baseline BMI does 
not predict CD4 change at 48  weeks (11  months) but 
Table 3 Multivariate predictors of  CD4 change 
at  6  months in  HIV-infected patients at  Jimma University 
Specialized Hospital, January 2006 to December 2011
Variables Number B [95 % CI] p value
Age 340 −3.4 [−5.5, −1.2] 0.003
Marital status
 Single 43 13.7 [−61.7, 89.2] 0.720
 Married 116 57.2 [−4.2, 118.7] 0.068
 Divorced 44 3.5 [−66.1, 73.1] 0.922
 Widowed 22 Reference
BMI
 <18.5 170 −12.4 [−48.8, 23.9] 0.5
 ≥18.5 170 Reference
Baseline co morbidity
 Yes 20 25.6 [−40.3, 91.4] 0.445
 No 320 Reference
CD4 count
 <100 5 126.9 [−13.8, 267.6] 0.077
 100–199 94 150.1 [10.2, 290.0] 0.036
 200–350 139 107.2 [−34.3, 248.7] 0.137
 >350 102 References
Table 4 Multivariate predictors of  CD4 change 
at 12 months in HIV-infected individuals at Jimma Univer-
sity Specialized Hospital, January 2006 to December 2011
Variables Numbers B [95 % CI] p value
Age 340 −1.91 [−3.238, −0.582] 0.005
Sex
 Female 200 Reference
 Male 140 −38.67 [−81.973, 4.633] 0.080
BMI
 <18.5 170 −21.54 [−64.197, 21.109] 0.321
 ≥18.5 170 Reference
HAART regimen
 Stavudine based 219 25.57 [−34.277, 85.420] 0.401
 Zidovudine based 72 −17.53 [−87.25, 52.190] 0.621
 Tenofovir based 49 Reference
Baseline CD4
 <100 5 188.75 [−9.859, 387.359] 0.062
 100–199 94 201.29 [2.916, 399.661] 0.047
 200–350 139 133.33 [−64.785, 81.773] 0.186
 >350 102 Reference
WHO stage
 Stage 1 65 Reference
 Stage 2 95 −15.96 [−78.139, 46.212] 0.614
 Stage 3 144 24.17 [−33.426, 81.773] 0.179
 Stage 4 36 −63.89 [−157.331, 29.548] 0.409
Educational status
 Not educated 69 Reference
 Primary 122 52.75 [−4.906, 110.408] 0.073
 Secondary 106 40.11 [−18.174, 98.400] 0.177
 Tertiary 42 40.113 [−76.277, 83.098] 0.933
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that this baseline BMI did predict CD4 change at 96 and 
144  weeks [13]. Lack of longterm outcomes related to 
baseline BMI in our study may be related to different eth-
nic background, geographical region, diet, smaller sam-
ple size and shorter follow-up period.
CD4 count at the initiation of treatment was sig-
nificantly associated with a change in CD4 at 6, and 
12  months when adjusted for other variables. A CD4 
count greater than 350  cells/mm3 at baseline was asso-
ciated with smaller increase in CD4 at 6 and 12 months 
in multivariable model compared to patients with lower 
CD4 counts. This finding was also documented in Lon-
don, UK where lower CD4 count was associated with 
greater increase in CD4 after 3  month of HAART ini-
tiation both in multivariable model [14]. In both our 
study and Bennett and his colleagues, females were 
found to have better CD4 recovery compared to males 
after at least a year of treatment [15]. Finally, we found 
that younger patients had greater increase in CD4 at 
6, 12, and 24  months similar to study in Europe which 
shows younger age favors CD4 cell restoration [16] and 
increasing age was risk factors for not achieving CD4 
count >200 [17]. Similarly, this finding is in line with 
the finding from study done in seven African countries 
which shows older age at HAART initiation was associ-
ated with suboptimal CD4 recovery CD4 [18]. Older age 
was independent predictor of mortality, which was com-
parable with study done in Johannesburg, South Africa 
which shows older patients were at greater risk of early 
death compared to younger patients [19]. Moreover, this 
finding was in line with study from South Eastern Nige-
ria and with what Adena et  al. reported which shows 
patients whose age greater than 45 were at greater risk of 
early death [20].
Malnourished patients were almost two times more 
likely to die early compared to well-nourished group 
though it is not significant in Multivariable Cox propor-
tional model. This finding was in line with study done 
in Zewditu Memorial hospital, Ethiopia which shows 
patients with BMI of <18.5 kg/m2 at the start of treatment 
were 1.13 [95  % CI 0.23, 5.43] times at greater risk of 
death compared to those with BMI >18.5 kg/m2 [21]. This 
Table 5 Multivariate predictors of  CD4 change 
at 24 months in HIV-infected individuals at Jimma Univer-
sity Specialized Hospital, January 2006 to December 2011
Variables Numbers 
of patients
B [95 % CI] p value




 Female 200 Reference




 Single 43 45.10 [−66.086, 
156.294]
0.424
 Married 116 138.56 [42.449, 
234.655]
0.005
 Divorced 44 52.47 [−55.935, 
160.873]
0.340
 Widowed 22 Reference
Baseline HAART





72 16.31 [−75.057, 
107.678]
0.724
 Tenofovir based 49 Reference
BMI
 <18.5 170 −22.42 [−81.040, 
36.202]
0.451
 ≥18.5 170 Reference
Educational level
 Not educated 69 −86.18 [−195.893, 
23.534]
0.123
 Elementary 122 12.63 [−89.442, 
114.698]
0.807
 Secondary 106 −38.30 [−139.605, 
63.006]
0.456
 Tertiary 42 Reference
Base line CD4
 <100 5 83.84 [−127.555, 
295.233]
0.434
 100–199 94 87.16 [−122.670, 
296.992]
0.413
 200–350 139 24.14 [−184.264, 
232.534]
0.819
 >350 102 Reference
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finding was also consistent with the finding from study 
done in Singapore where patients with BMI less than 
18.5 were 1.4 times more likely to die early compared to 
patients with BMI greater than or equal to 18.5  kg/m2 
[12]. Studies in Tanzania and Malawi where malnour-
ished patients were associated with early death compared 
to well-nourished group [22, 23]. Likewise, Raoul and his 
colleagues reported low BMI was an independent predic-
tor of death in West Africa [18]. Other studies [13–15] 
also reported BMI as an important predictor of death.
Tenofovir based regimen was associated with highest 
risk of death compared to Stavudine and Zidovudine 
based regimen. This is similar with what Kelechi and 
his colleagues reported [24] but in contrast to the find-
ing South Africa which shows there was no difference in 
mortality between Tenofovir and Stavudine [19]. Again 
different ethnic background, geographical region, diet, 
smaller sample size and shorter follow-up period in our 
study. Furthermore, single antiretroviral drugs were 
compared in our study while Kavindhran et al. [19] com-
pared regimens of three or more antiretroviral drugs.
Independent of specific antiretrovirals, Flucona-
zole prophylaxis was found to be strong predictor of 
death in our study and indifference to a Uganda study 
suggesting that this antifungal did not impact mortal-
ity under similar conditions [25]. Most patients in our 
study took fluconazole when CD4 cell counts were 
<200/ml.
Conclusion
BMI at the start did not predict change in CD4 at any 
time point after initiation of HAART after adjustment for 
other variables.
Age of the patients was significant predictor of immu-
nologic outcome at 6, 12, 24 months adjusting for other 
factors. Baseline CD4 count was significant predictor of 
CD4 change at 12 months. Sex was significant predictor 
of immunologic outcome at 24 months after HAART ini-
tiation. At 24th month baseline HAART and marital sta-
tus predicts immunologic outcome.
Age >50 years of age, Tenofovir based regimen, Zido-
vudine based regimen, taking fluconazole and CD4 <200 
were associated with greater risk of death.
Malnutrition at the start of HAART does not predict 
early death of patients.
Fig. 1 Kaplan–Meier plots of nutritional status in HIV infected individuals in cohort of patients at Jimma University specialized hospital, January 
2006 to December 2011
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